Literature DB >> 26766222

Practice Pattern Variation in the Care of Children With Acute Asthma.

James M Chamberlain1, Stephen J Teach1, Katie L Hayes1, Gia Badolato1, Monika K Goyal1.   

Abstract

OBJECTIVES: Pediatric asthma is a highly prevalent disease, affecting over 7 million U.S. children and accounting for 750,000 annual emergency department (ED) visits. Guidelines from the National Asthma Education and Prevention Program recommend limited use of chest radiography (CXR), complete blood counts (CBCs), and antibiotics when managing acute exacerbations of asthma. However, studies suggest frequent overutilization of these resources. The objective was to evaluate differences between pediatric and general EDs in rates of CXRs, CBCs, and use of antibiotics for pediatric asthma exacerbations.
METHODS: This was a repeated cross-sectional analysis of data from the National Hospital Ambulatory Medical Care Survey from 2000 through 2010 of CXR, CBCs, and antibiotics during ED visits for pediatric acute asthma exacerbations. Multivariable logistic regression was performed to identify differences in asthma management by ED type (pediatric vs. general) after adjusting for demographic covariates.
RESULTS: There were 3,313 observations, representing an estimated 10.9 million (95% confidence interval [CI] = 9.7 to 12.1 million) ED visits for acute asthma without bacterial coinfection. Of these, 17.4% occurred in pediatric EDs. Multivariable logistic regression revealed that visits to pediatric EDs were less likely to include CXRs (adjusted odds ratio [AOR] = 0.39; 95% CI = 0.25 to 0.60), CBCs (AOR = 0.42; 95% CI = 0.22 to 0.80), and antibiotics (AOR = 0.50; 95% CI = 0.31 to 0.82) after adjustment for race/ethnicity, triage level, academic ED, metropolitan statistical area, and geographic region.
CONCLUSIONS: There are substantial differences in diagnostic testing and antibiotic usage for management of acute exacerbations of asthma by ED type, suggesting potential resource overuse in general EDs. Future studies should focus on evaluating the effect of quality improvement efforts for ED asthma management.
© 2016 by the Society for Academic Emergency Medicine.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26766222     DOI: 10.1111/acem.12857

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  5 in total

1.  A Multifaceted Intervention Improves Prescribing for Acute Respiratory Infection for Adults and Children in Emergency Department and Urgent Care Settings.

Authors:  Kabir Yadav; Daniella Meeker; Rakesh D Mistry; Jason N Doctor; Katherine E Fleming-Dutra; Ross J Fleischman; Samuel D Gaona; Aubyn Stahmer; Larissa May
Journal:  Acad Emerg Med       Date:  2019-06-19       Impact factor: 3.451

2.  Racial and Ethnic Disparities in Acute Care Use for Pediatric Asthma.

Authors:  Jorge Kaufmann; Miguel Marino; Jennifer Lucas; Steffani R Bailey; Sophia Giebultowicz; Jon Puro; David Ezekiel-Herrera; Shakira F Suglia; John Heintzman
Journal:  Ann Fam Med       Date:  2022 Mar-Apr       Impact factor: 5.166

3.  A Qualitative Study Examining Stakeholder Perspectives of a Local Child Abuse Program in Community Emergency Departments.

Authors:  Gunjan Tiyyagura; Paula Schaeffer; Marcie Gawel; John M Leventhal; Marc Auerbach; Andrea G Asnes
Journal:  Acad Pediatr       Date:  2019-01-29       Impact factor: 3.107

4.  Adherence to guideline recommendations for asthma care in community pharmacies: actual and needed performance.

Authors:  Esther Kuipers; Michel Wensing; Elaine Wong-Go; Bernard J G Daemen; Peter A G M De Smet; Martina Teichert
Journal:  NPJ Prim Care Respir Med       Date:  2019-07-11       Impact factor: 2.871

5.  Assessing the appropriateness of paediatric antibiotic overuse in Australian children: a population-based sample survey.

Authors:  Gaston Arnolda; Peter Hibbert; Hsuen P Ting; Charli Molloy; Louise Wiles; Meagan Warwick; Tom Snelling; Nusrat Homaira; Adam Jaffe; Jeffrey Braithwaite
Journal:  BMC Pediatr       Date:  2020-04-24       Impact factor: 2.125

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.